Record Details

Leishmanial Antigens in Liposomes Promote Protective Immunity and Provide Immunotherapy Against Visceral Leishmaniasis via Polarized Th1 Response

EPrints@IICB

View Archive Info
 
 
Field Value
 
Title Leishmanial Antigens in Liposomes Promote Protective Immunity and Provide Immunotherapy Against Visceral Leishmaniasis
via Polarized Th1 Response
 
Creator Bhowmick, Sudipta
Ravindran, Rajesh
Ali, Nahid
 
Subject Infectious Diseases and Immunology
 
Description Leishmaniasis affects 12 million people, and it is generally agreed that vaccination provides the best long-term strategy for its control. An
ideal vaccine should be effective in both preventing and treating leishmaniasis. However, immunological correlates to predict vaccine efficacy
and success of treatment in visceral leishmaniasis (VL) remain ill defined. Here, we correlated the vaccine efficacy of soluble leishmanial
antigens (SLA) from Leishmania donovani promastigote membrane, entrapped in negative, neutral and positively charged liposomes with
the elicited immune responses to predict vaccine success in experimental VL. Production of both IFN-� and IL-4 with a dominance of
Th1 response following immunization was required for optimum success against L. donovani infection in BALB/c mice. The best vaccine
formulation, SLA in positively charged liposomes, was then used for immunotherapy. This vaccine induced more than 90% elimination of
parasites from both liver and spleen. The success of immunotherapy exhibited an immune modulation with surge in Th1 cytokines, IFN-�
and IL-12 with extreme down regulation of disease promoting IL-4 and IL-10. These findings suggest that an immune modulation towards
Th1 is effective for both successful vaccination and immunotherapy.
 
Date 2007
 
Type Article
PeerReviewed
 
Format application/pdf
 
Identifier http://www.eprints.iicb.res.in/1161/1/VACCINE__25(_35)_6544%2D6556;2007[47].pdf
Bhowmick, Sudipta and Ravindran, Rajesh and Ali, Nahid (2007) Leishmanial Antigens in Liposomes Promote Protective Immunity and Provide Immunotherapy Against Visceral Leishmaniasis via Polarized Th1 Response. Vaccine, 25 (35). pp. 6544-6556.
 
Relation http:/dx.doi.org/:10.1016/j.vaccine.2007.05.042
http://www.eprints.iicb.res.in/1161/